UPDATE: Oppenheimer Upgrades Seattle Genetics To Outperform, Raises Target To $82 Based On Firm's Review 'of two pipeline assets (Enfortumab Vedotin and tucatinib) that focus on less competitive later lines of treatment with strong data'